said. Stepwise treatment to manage flare-ups depends on patient factors and asthma severity. ... Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med.
QD: News Every Day--Azithromycin may benefit non-eosinophilic severe asthma exacerbations. Azithromycin did not reduce the rate of severe exacerbations and lower respiratory tract infections in patients with severe asthma, ... But, azithromycin was
IM 2012: It might not be asthma. During a session on diagnostic challenges in allergies (see tomorrow's Internal Medicine 2012 News for more on that), allergist Raymond Slavin, MD, MACP, ... We see it more and more often and it is very often confused
What I learned from asthma. As a kid I had allergies and asthma. ... Asthma has played a minimal role in my adult life. Only occasionally do I use my albuterol inhaler before I run.
Conversely, the presence of asthma in a patient's history can also confound diagnosis. ... Making this particularly tricky, asthma is a risk factor for anaphylaxis and increases the risk of death from an allergic reaction, especially in teens.
QD: News Every Day--Gene variants in asthma diminish steroid inhaler's efficacy. ... Less than 4% of those who drank 1 to 6 units per week developed asthma.
comorbid. Every asthma or allergy patient has a story, according to John M. ... Another categorization challenge is whether severity should change if asthma improves with treatment.
All trials were randomized controlled trials of children with allergic asthma or rhinoconjunctivitis. ... improved asthma and rhinitis symptoms and low strength of evidence that injections improved conjunctivitis symptoms and asthma medication scores.
QD: News Every Day--Asthma rates rising amid falling budgets to treat it. ... Women were more likely than men and boys more likely than girls to have asthma.
In 2007, an estimated 3.8 million children suffered an asthma attack or episode. ... Genome-wide association studies are also being employed to unravel the pharmacogenomics of asthma drug responsiveness.